Dongling Zhu,Dong Kuang,Sijuan Zou,Lixing Chen,Yuanli Zhu,Xiaohua Zhu. Immunohistochemical panel of glypican-3 hepatocyte paraffin antigen-1, arginase-1, cytokeratin-19, and human epithelial membrane antigen for the differential diagnosis of liver tumors. Oncol Transl Med, 2019, 5: 153-161. |
Immunohistochemical panel of glypican-3 hepatocyte paraffin antigen-1, arginase-1, cytokeratin-19, and human epithelial membrane antigen for the differential diagnosis of liver tumors |
Received:April 16, 2019 Revised:August 29, 2019 |
View Full Text View/Add Comment Download reader |
KeyWord:hepatocellular carcinoma (HCC); intrahepatic cholangiocarcinoma (ICC); combined hepatocellular and cholangiocarcinoma (CHC); immunohistochemistry |
Author Name | Affiliation | E-mail | Dongling Zhu | Department of Nuclear Medicine and PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | 714257103@qq.com | Dong Kuang | Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | Sijuan Zou | Department of Nuclear Medicine and PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | Lixing Chen | Department of Nuclear Medicine and PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | Yuanli Zhu | Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | Xiaohua Zhu | Department of Nuclear Medicine and PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | evazhu@vip.sina.com |
|
Hits: 6097 |
Download times: 6659 |
Abstract: |
Objective Clinical immunohistochemistry plays an increasingly important role in pathologic diagnosis.
We investigated the usefulness of an immunohistochemical panel of glypican-3 (GPC3), hepatocyte
paraffin antigen-1 (HepPar-1), arginase-1 (Arg-1), cytokeratin-19 (CK19), and human epithelial membrane
antigen (EMA) for the differential diagnosis of liver tumors.
Methods Two hundred and thirty-five immunohistochemical sections of hepatocellular carcinoma
(HCC; 120 cases), intrahepatic cholangiocarcinoma (ICC; 50 cases), combined hepatocellular and
cholangiocarcinoma (CHC; 17 cases), metastatic adenocarcinoma (20 cases), and benign liver lesions
(28 cases) were obtained from the Department of Pathology at Tongji Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, China. The sensitivity and specificity of the
combined biomarkers GPC3/HepPar-1/Arg-1/CK19/EMA for the differential diagnosis of HCC, ICC, and
CHC were calculated and analyzed retrospectively.
Results The combined biomarkers GPC3+/CK19– had the highest specificity (98.3%) for diagnosing
HCC, with a sensitivity of 60.0%. The specificity of GPC3–/HepPar-1–/Arg-1–/CK19+/EMA+ for diagnosing
ICC was 93.0%, with a sensitivity of 76.0%. The specificity of GPC3+/HepPar-1+/Arg-1+/CK19+/EMA+ for
diagnosing CHC was 95.9%, with a sensitivity of 52.9%.
Conclusion The combined biomarkers GPC3/HepPar-1/Arg-1/CK19/EMA greatly improved the
specificity of liver tumor diagnosis. We believe that clinical pathological work could improve the original
determination of liver nodules. |
Close |
|
|
|